Notre équipe

Guillain-Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study. Cabon J, Ducloie M, Chretien B, Arnaud C, Alexandre J, Dolladille C, Da Silva A. J Neurol. 2025;273(1):27. doi: 10.1007/s00415-025-13507-0.

Analysis of anticancer drug associated adverse reactions in depressive patients from vigibase. Chretien B, Dolladille C, Nishida K, Aleksic B, Alexandre J, L'orphelin JM. Sci Rep. 2025;15(1):45751. doi: 10.1038/s41598-025-28563-9.

Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study. Font J, Hodzic A, Da-Silva A, Delapierre B, Damaj G, Neusy A, Plane AF, Legallois D, Milliez P, Dolladille C, Vernon M, Burton S, Vigneron N, Denoyelle C, Alexandre J. Biomedicines. 2025;13(9):2184. doi: 10.3390/biomedicines13092184.

Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Power JR, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas NL, Lehmann LH, Cautela J, Courand PY, Hayek SS, Zhu H, Zaha VG, Cheng RK, Alexandre J, Roubille F, Baldassarre LA, Chen YC, Baik AH, Laufer-Perl M, Tamura Y, Asnani A, Francis S, Gaughan EM, Rainer PP, Bailly G, Flint D, Arangalage D, Cariou E, Florido R, Narezkina A, Liu Y, Sandhu S, Leong D, Issa N, Piriou N, Heinzerling L, Peretto G, Crusz SM, Akhter N, Levenson JE, Turker I, Eslami A, Fenioux C, Moliner P, Obeid M, Chan WT, Ewer SM, Kassaian SE, Johnson DB, Nohria A, Ben Zadok OI, Moslehi JJ, Salem JE; International ICI-Myocarditis Registry. Eur Heart J. 2025:ehaf315. doi: 10.1093/eurheartj/ehaf315.

Identification of Anticancer Drugs Associated With Cancer Therapy-Related Cardiac Dysfunction in Pediatrics-Analysis of the WHO Pharmacovigilance Database. Labombarda F, Rouger J, Legallois D, Dolladille C, Alexandre J, Chrétien B. Pediatr Blood Cancer. 2025 Jul;72(7):e31727. doi: 10.1002/pbc.31727.

Identification of Anticancer Drugs Associated to Cancer Therapy-Related Cardiac Dysfunction: A VigiBase® Disproportionality Analysis. Legallois D, Da Silva A, Alexandre J, Milliez P, Sabatier R, Blanchart K, Plane AF, Font J, ChréTien B, Dolladille C. Eur Heart J Cardiovasc Pharmacother. 2025:pvaf027. doi: 10.1093/ehjcvp/pvaf027.

Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis. Alexandre J, Font J, Lenormand T, Chantepie S, Bardet H, Damaj G, Dolladille C, Legallois D, Da-Silva A, Milliez P, Bisson A, Fauchier L. Exp Hematol Oncol. 2025;14(1):29. doi: 10.1186/s40164-025-00619-6.

SGLT2 Inhibitors in Cancer Patients: A Paradigm Shift in Cardio-Oncology? Cautela J, Alexandre J. Eur J Prev Cardiol. 2025. doi: 10.1093/eurjpc/zwaf146

Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction. Chen YC, Dolladille C, Rao A, Palaskas NL, Deswal A, Lehmann L, Cautela J, Courand PY, Hayek S, Zhu H, Cheng RK, Alexandre J, Baldassarre LA, Roubille F, Laufer-Perl M, Asnani A, Ederhy S, Tamura Y, Francis S, Gaughan EM, Johnson DB, Flint DL, Rainer PP, Bailly G, Ewer SM, Aras MA, Arangalage D, Cariou E, Florido R, Peretto G, Itzhaki Ben Zadok O, Akhter N, Narezkina A, Levenson JE, Liu Y, Crusz SM, Issa N, Piriou N, Leong D, Sandhu S, Turker I, Moliner P, Obeid M, Heinzerling L, Chang WT, Stewart A, Venkatesh V, Du Z, Yadavalli A, Kim D, Chandra A, Zhang KW, Power JR, Moslehi J, Salem JE, Zaha VG; International ICI Myocarditis Registry. JACC CardioOncol. 2025;7(3):234-248. doi: 10.1016/j.jaccao.2025.01.020.

Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Travers S, Alexandre J, Baldassarre LA, Salem JE, Mirabel M. Arch Cardiovasc Dis. 2025. doi: 10.1016/j.acvd.2024.12.012.

BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort study. Ezine E, Da Silva A, Idoudi S, Lebbe C, Chrétien B, Sassier M, Alexandre J, Dolladille C. Therapie. 2025. doi: 10.1016/j.therap.2024.12.011.

Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals. L'Orphelin JM, Da Silva A, Cabon J, Alexandre J, Dolladille C. BMJ Open. 2024;14(12):e091708. doi: 10.1136/bmjopen-2024-091708.

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database. Morice PM, Khalife-Hachem S, Sassier M, Lelong-Boulouard V, Danu A, Pasquier F, Renneville A, Dolladille C, Micol JB. Blood Cancer J. 2024;14(1):177. doi: 10.1038/s41408-024-01154-z.

Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database. Alexandre J, Font J, Angélique DS, Delapierre B, Damaj G, Plane AF, Legallois D, Milliez P, Dolladille C, Chrétien B. Leukemia. 2024;38(12):2628-2635. doi: 10.1038/s41375-024-02413-5.

Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity. Power JR, Dolladille C, Ozbay B, Procureur AM, Ederhy S, Palaskas NL, Lehmann LH, Cautela J, Courand PY, Hayek SS, Zhu H, Zaha VG, Cheng RK, Alexandre J, Roubille F, Baldassarre LA, Chen YC, Baik AH, Laufer-Perl M, Tamura Y, Asnani A, Francis S, Gaughan EM, Rainer PP, Bailly G, Flint D, Arangalage D, Cariou E, Florido R, Narezkina A, Liu Y, Sandhu S, Leong D, Issa N, Piriou N, Heinzerling L, Peretto G, Crusz SM, Akhter N, Levenson JE, Turker I, Eslami A, Fenioux C, Moliner P, Obeid M, Chan WT, Ewer SM, Kassaian SE; International ICI-Myocarditis Registry; Johnson DB, Nohria A, Zadok OIB, Moslehi JJ, Salem JE. medRxiv [Preprint]. 2024. doi: 10.1101/2024.06.02.24308336.

Arterial hypertension associated with PARPi: A meta-analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study. Blaize C, Surtouque E, Font J, Dolladille C, Postel-Vinay S, Da Silva A, Alexandre J, Morice PM. Fundam Clin Pharmacol. 2024;38(4):610-629. doi: 10.1111/fcp.12984.

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database. Prevost R, Chretien B, Minoc EM, Dolladille C, Da-Silva A, Nehme A, Joly F, Lelong-Boulouard V, Bastien E. Front Pharmacol. 2023;14:1278682. doi: 10.3389/fphar.2023.1278682.

Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J; International ICI-Myocarditis Registry; Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE.
Nat Med. 2023;29(12):3100-3110. doi: 10.1038/s41591-023-02591-2.

Cardiologist-Performed Baseline Evaluation with an Assessment of Coronary Status for Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Impact on Newly Diagnosed Coronary Artery Disease. Rogé M, Guimas V, Rio E, Vaugier L, Perennec T, Alexandre J, Supiot S, Martin Mervoyer E. Cancers (Basel). 2023;15(16):4157. doi: 10.3390/cancers15164157.

Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials. Alexandre J, Boismoreau L, Morice PM, Sassier M, Da-Silva A, Plane AF, Font J, Milliez P, Legallois D, Dolladille C. JACC CardioOncol. 2023;5(2):216-226. doi: 10.1016/j.jaccao.2022.11.019.

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma. L'Orphelin JM, Dollalille C, Akroun J, Alexandre J, Dompmartin A. Cancers (Basel). 2023;15(7):2170. doi: 10.3390/cancers15072170.

Diagnostic Value of the International Society of Cardio-Oncology Definition for Suspected Immune Checkpoint Inhibitor-Associated Myocarditis. Deharo F, Thuny F, Cadour F, Resseguier N, Meilhac A, Gaubert M, Dolladille C, Paganelli F, Alexandre J, Cautela J. J Am Heart Assoc. 2023;12(8):e029211. doi: 10.1161/JAHA.122.029211.

Atrial fibrillation, cancer and anticancer drugs. Font J, Milliez P, Ouazar AB, Klok FA, Alexandre J. Arch Cardiovasc Dis. 2023;116(4):219-226. doi: 10.1016/j.acvd.2023.02.005.

Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek SS, Asnani A, Tamura Y, Aras M, Cautela J, Thuny F, Gilstrap L, Arangalage D, Ewer S, Huang S, Deswal A, Palaskas NL, Finke D, Lehmann LH, Ederhy S, Moslehi J, Salem JE; International ICI-Myocarditis Registry. Arch Cardiovasc Dis. 2022;115(5):315-330. doi: 10.1016/j.acvd.2022.03.003.

[¹⁷⁷Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database. Vigne J, Chrétien B, Bignon AL, Bouhier-Leporrier K, Dolladille C.
Eur J Nucl Med Mol Imaging. 2022;49(10):3332-3333. doi: 10.1007/s00259-022-05833-6.

Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, Hekimian G, Ammirati E, Ben M'Barek B, Redheuil A, Gandjbakhch E, Bihan K, Lebrun-Vignes B, Ederhy S, Dolladille C, Moslehi JJ, Salem JE. Nat Commun. 2022;13(1):25. doi: 10.1038/s41467-021-27631-8.

Androgens, QT, sex and ventricular repolarization. Alexandre J, Puddu PE. Therapie. 2022;77(3):257-258. doi: 10.1016/j.therap.2021.12.011.

Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, Tamura Y, Aras M, Cautela J, Thuny F, Gilstrap L, Arangalage D, Ewer S, Huang S, Deswal A, Palaskas NL, Finke D, Lehman L, Ederhy S, Moslehi J, Salem JE; International ICI-Myocarditis Registry†. Circulation. 2021;144(18):1521-1523. doi: 10.1161/CIRCULATIONAHA.121.055816.

Occurrence of Pancytopenia Among Patients With Cancer Treated With Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitors: A Pharmacoepidemiologic Study. Morice PM, Chrétien B, Da Silva A, Dolladille C, Alexandre J. JAMA Oncol. 2021;7(12):1899-1900. doi: 10.1001/jamaoncol.2021.4672.

Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres. Morice PM, Genthon A, Boyer T, Bihan K, Mahé J, Sourisseau A, Peyrouzet H, Miremont G, Lepelley M, Stefani L, Gaboriau L, Rocher F, Aquaronne D, Le Beller C, Allouchery M, Azzouz B, Massy N, Alt-Tebacher M, Simand C, Herbrecht R, Chrétien B, Dolladille C, Chantepie S, Alexandre J.
Br J Haematol. 2022;196(3):787-793. doi: 10.1111/bjh.17863.

Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E, Sassier M, Da-Silva A, Plane AF, Legallois D, L'Orphelin JM, Alexandre J. Eur Heart J. 2021;42(48):4964-4977. doi: 10.1093/eurheartj/ehab618.

Management of Immune Checkpoint Inhibitor-Induced Myocarditis: The French Working Group's Plea for a Pragmatic Approach. Thuny F, Alexandre J, Salem JE, Mirabel M, Dolladille C, Cohen-Solal A, Cohen A, Ederhy S, Cautela J; French Working Group of Cardio-Oncology. JACC CardioOncol. 2021;3(1):157-161. doi: 10.1016/j.jaccao.2020.12.001.

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, Alexandre J, Rassaf T, Müller OJ, Aras M, Asnani AH, Deswal A, Laufer-Perl M, Thuny F, Kerneis M, Hayek SS, Ederhy S, Salem JE, Moslehi JJ. JAMA Cardiol. 2021;6(11):1329-1337. doi: 10.1001/jamacardio.2021.2241.

Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis. Dolladille C, Chrétien B, Peyro-Saint-Paul L, Alexandre J, Dejardin O, Fedrizzi S, Defer G. Neurotherapeutics. 2021;18(3):1657-1664. doi: 10.1007/s13311-021-01073-y.

Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study. Dolladille C, Ederhy S, Ezine E, Choquet S, Nguyen LS, Alexandre J, Moslehi JJ, Dechartres A, Salem JE. Am J Hematol. 2021;96(9):1101-1111.

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, Moore K, O'Reilly EM, Ray-Coquard I, Alexandre J. Lancet Haematol. 2021;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4.

Abemaciclib-induced reversible grade 4 nephrotoxicity. Da Silva A, Chretien B, Alexandre J, Emile G.
Breast J. 2020;26(11):2329-2330. doi: 10.1111/tbj.13980.

Association Between Use of Anticancer Drugs and Cardiovascular Disease-Related Hospitalization in Metastatic Colorectal Cancer: Insights From a Population-Based Study, the Anticancer Vigilance of Cardiac Events Study. Dolladille C, Launoy G, Bouvier V, Salem JE, Legallois D, Milliez P, Sassier M, Lobbedez T, Guittet L, Alexandre J.
Am J Epidemiol. 2021;190(3):376-385. doi: 10.1093/aje/kwaa203.

Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, Farnault L, Charbonnier A, Mirabel M, Champiat S, Cohen-Solal A, Cohen A, Dolladille C, Thuny F. J Am Heart Assoc. 2020;9(18):e018403. doi: 10.1161/JAHA.120.018403.

Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis. Dolladille C, Font J, Bejan-Angoulvant T, Zaman K, Sassier M, Ezine E, Stefan A, Plane AF, Legallois D, Milliez P, Parienti JJ, Alexandre J. Arch Cardiovasc Dis. 2020;113(6-7):420-432.

Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, Thuny F, Ederhy S, Cohen A, Damaj G, Vilque JP, Plane AF, Legallois D, Champ-Rigot L, Milliez P, Funck-Brentano C, Dolladille C. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312-320. doi: 10.1093/ehjcvp/pvaa037.

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J. JAMA Oncol. 2020;6(6):865-871. doi: 10.1001/jamaoncol.2020.0726.

Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and/or percutaneous coronary intervention. Roule V, Verdier L, Blanchart K, Ardouin P, Lemaitre A, Bignon M, Sabatier R, Alexandre J, Beygui F. BMC Cardiovasc Disord. 2020;20(1):38. doi: 10.1186/s12872-020-01352-0.

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, Sassier M, Plane AF, Comoz F, Cohen AA, Thuny FR, Cautela J, Alexandre J. J Immunother Cancer. 2020;8(1):e000261. doi: 10.1136/jitc-2019-000261.

High incidence of atrial fibrillation in patients treated with ibrutinib. Baptiste F, Cautela J, Ancedy Y, Resseguier N, Aurran T, Farnault L, Escudier M, Ammar C, Gaubert M, Dolladille C, Barraud J, Peyrol M, Cohen A, Paganelli F, Alexandre J, Ederhy S, Thuny F. Open Heart. 2019;6(1):e001049. doi: 10.1136/openhrt-2019-001049.

Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Pharmacol Ther. 2018;189:89-103. doi: 10.1016/j.pharmthera.2018.04.009.